No abstract

Psoriasis is a chronic inflammatory skin disease with several triggering factors, such as trauma, drugs, stress, alcohol and vaccination. 1 On March 11, 2020, the World Health Organization declared coronavirus disease 2019 (COVID-19) a novel pandemic. Numerous vaccines against SARS-CoV-2 have been developed, and some have received emergency use authorization to prevent COVID-19 pneumonia or reduce disease severity. As of June 2021, 4 vaccine platforms-mRNA, viral vector, inactivated whole virus and recombinant protein-had entered the stage of emergency use authorization and precertification evaluation. 2 Although none had been testedin randomized clinical trials in patients with psoriasis, the National Psoriasis Foundation recommended that all patients with psoriasis should receive a vaccine as soon as it is available, as the benefits outweigh the risks. [3][4][5] The International Psoriasis Council also stated that registry data should be collected to determine the positive or negative effects of COVID-19 vaccines on psoriasis outcomes. 3,6

Bimatoprost ophthalmic solution 0.03% (PGF2α analogues) combined with narrowband ultraviolet B (NB-UVB) was reported to be an effective treatment for vitiligo. To investigate the efficacy and safety of treatment for non-segmental/segmental vitiligo compared among bimatoprost ophthalmic solution 0.01% combined with NB-UVB phototherapy, bimatoprost monotherapy, and placebo. This single-blind randomized controlled study enrolled stable Thai vitiligo patients with at least three similarly sized lesions in the same anatomical area. The treatment duration was 6 months with 1- and 2-month post-treatment follow-ups. The 3 selected lesions on each patient were randomized to receive combination therapy, monotherapy, or placebo. The Vitiligo Area Scoring Index (VASI) was used to evaluate lesion response. Of the 25 initially enrolled subjects, 19 patients were analyzed. There were 13 and 6 non-segmental and segmental vitiligo cases, respectively. Eight and 11 cases had face/neck and non-face/neck lesions, respectively. Non-segmental vitiligo and non-face/neck vitiligo patients in the combination group had significant improvement in VASI score at 3 months, 6 months, and at the 2-month follow-up. No side effects were observed/reported. Bimatoprost combination therapy was shown to be safe and effective for treating Thai patients with non-segmental vitiligo in non-face/neck areas of the body.